Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09VQM
|
|||
| Former ID |
DIB020494
|
|||
| Drug Name |
naringin
|
|||
| Synonyms |
Naringoside; AC1NR4U8; 4',5,7-Trihydroxyflavanone-7-rutinoside; 4',5,7-Trihydroxyflavanone-7-rhamnoglucoside
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H32O14
|
|||
| Canonical SMILES |
CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O
|
|||
| InChI |
1S/C27H32O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-7,10,16,18,20-30,32-36H,8-9H2,1H3/t10-,16-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1
|
|||
| InChIKey |
DFPMSGMNTNDNHN-ZPHOTFPESA-N
|
|||
| CAS Number |
CAS 10236-47-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:28819
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium dentium
Show/Hide Hierarchy
|
[2], [3] | |||
| Hierarchy | ||||
| Microbial Enzyme | Alpha-L-rhamnosidase | |||
| Metabolic Effect | Decrease activity | |||
| Description | Naringin can be metabolized by the alpha-L-rhamnosidase of Bifidobacterium dentium, which results in the decrease of the drug's activity. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [4] | |||
| Microbial Enzyme | Beta glucosidase | |||
| Metabolic Reaction | Hydrolysis | |||
| Resulting Metabolite | Naringenin | |||
| Metabolic Effect | Increase activity | |||
| Description | Naringin can be metabolized to Naringenin by the beta glucosidase of gut microbiota through hydrolysis, which results in the increase of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium-independent organic anion transporter (SLCO1A2) | Target Info | Inhibitor | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4738). | |||
| REF 2 | Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1043-1055. | |||
| REF 3 | Metabolism of rutin and poncirin by human intestinal microbiota and cloning of their metabolizing Alpha-L-rhamnosidase from Bifidobacterium dentium. J Microbiol Biotechnol. 2015 Jan;25(1):18-25. | |||
| REF 4 | Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 2012 Nov 30;4(1):16. | |||
| REF 5 | Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther. 2007 Apr;81(4):495-502. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.